CA3171267A1 - A combination therapy with nirogacestat and a bcma-directed therapy and uses thereof - Google Patents

A combination therapy with nirogacestat and a bcma-directed therapy and uses thereof Download PDF

Info

Publication number
CA3171267A1
CA3171267A1 CA3171267A CA3171267A CA3171267A1 CA 3171267 A1 CA3171267 A1 CA 3171267A1 CA 3171267 A CA3171267 A CA 3171267A CA 3171267 A CA3171267 A CA 3171267A CA 3171267 A1 CA3171267 A1 CA 3171267A1
Authority
CA
Canada
Prior art keywords
subject
bcma
nirogacestat
dihydrobromide
therapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3171267A
Other languages
English (en)
French (fr)
Inventor
Todd Webster SHEARER
Badreddin EDRIS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SpringWorks Therapeutics Inc
Original Assignee
SpringWorks Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SpringWorks Therapeutics Inc filed Critical SpringWorks Therapeutics Inc
Publication of CA3171267A1 publication Critical patent/CA3171267A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001116—Receptors for cytokines
    • A61K39/001117—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR] or CD30
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4214—Receptors for cytokines
    • A61K40/4215—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/804—Blood cells [leukemia, lymphoma]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
CA3171267A 2020-03-13 2021-03-12 A combination therapy with nirogacestat and a bcma-directed therapy and uses thereof Pending CA3171267A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062989372P 2020-03-13 2020-03-13
US62/989,372 2020-03-13
PCT/US2021/022177 WO2021183934A1 (en) 2020-03-13 2021-03-12 A combination therapy with nirogacestat and a bcma-directed therapy and uses thereof

Publications (1)

Publication Number Publication Date
CA3171267A1 true CA3171267A1 (en) 2021-09-16

Family

ID=75396879

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3171267A Pending CA3171267A1 (en) 2020-03-13 2021-03-12 A combination therapy with nirogacestat and a bcma-directed therapy and uses thereof

Country Status (17)

Country Link
US (1) US20230121547A1 (OSRAM)
EP (1) EP4132515A1 (OSRAM)
JP (2) JP7781764B2 (OSRAM)
KR (1) KR20230009873A (OSRAM)
CN (1) CN115916188A (OSRAM)
AR (1) AR121566A1 (OSRAM)
AU (1) AU2021236340A1 (OSRAM)
BR (1) BR112022018251A2 (OSRAM)
CA (1) CA3171267A1 (OSRAM)
CL (1) CL2022002479A1 (OSRAM)
CO (1) CO2022014388A2 (OSRAM)
IL (1) IL296075A (OSRAM)
MX (1) MX2022011258A (OSRAM)
PE (1) PE20230614A1 (OSRAM)
TW (1) TW202200132A (OSRAM)
WO (1) WO2021183934A1 (OSRAM)
ZA (1) ZA202209989B (OSRAM)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI905452B (zh) 2021-09-01 2025-11-21 美商斯普林渥克斯治療有限公司 尼羅司他（ｎｉｒｏｇａｃｅｓｔａｔ）之合成
WO2023064872A1 (en) * 2021-10-14 2023-04-20 Precision Biosciences, Inc. Combinations of anti-bcma car t cells and gamma secretase inhibitors
CN118338900A (zh) * 2021-11-05 2024-07-12 斯普林渥克斯治疗有限公司 含尼罗加司他的组合物和治疗
CA3239013A1 (en) * 2021-11-23 2023-06-01 Anantha Rajmohan MUTHUSAMY Solid state forms of nirogacestat salts
US11951096B2 (en) 2022-05-20 2024-04-09 Springworks Therapeutics, Inc. Treatments with nirogacestat
US12138246B2 (en) 2022-05-20 2024-11-12 Springworks Therapeutics, Inc. Treatments with nirogacestat
US12036207B2 (en) 2022-05-20 2024-07-16 Springworks Therapeutics, Inc. Treatments with nirogacestat
CN119486713A (zh) 2022-05-20 2025-02-18 斯普林渥克斯治疗有限公司 尼罗加司他治疗
EP4678635A1 (en) * 2023-03-09 2026-01-14 Crystal Pharmaceutical (Suzhou) Co., Ltd. Crystal form of nirogacestat dihydrobromate, and preparation method therefor and use thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015120065A1 (en) * 2014-02-05 2015-08-13 The Trustees Of Columbia University In The City Of New York Gamma-secretase inhibition reduce apoc3 levels and plasma triglycerides
EP3662909A1 (en) * 2015-07-24 2020-06-10 Oncotracker, Inc. Gamma secretase modulators for the treatment of immune system dysfunction
JP2020507605A (ja) * 2017-02-17 2020-03-12 フレッド ハッチンソン キャンサー リサーチ センター Ｂｃｍａ関連癌および自己免疫疾患の治療のための併用療法
US20200055948A1 (en) * 2017-04-28 2020-02-20 Novartis Ag Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
US20200179511A1 (en) * 2017-04-28 2020-06-11 Novartis Ag Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
CN110622566B (zh) 2017-05-05 2021-04-20 华为技术有限公司 一种辅助数据传输方法、设备及系统
EP3706754A1 (en) * 2017-11-06 2020-09-16 Juno Therapeutics, Inc. Combination of a cell therapy and a gamma secretase inhibitor
WO2019094626A1 (en) * 2017-11-08 2019-05-16 Fred Hutchinson Cancer Research Center Bispecific antibody compositions and related methods for improved pretargeted radioimunotherapies
US20210069194A1 (en) * 2018-01-17 2021-03-11 Mingsight Pharmaceuticals, Inc. Combination therapy for the treatment of cancer
CA3101340A1 (en) * 2018-05-24 2019-11-28 Ayala Pharmaceuticals Inc. Compositions comprising bisfluoroalkyl-1,4-benzodiazepinone compounds and immunotherapeutics and methods of use thereof
AU2019277029C1 (en) * 2018-06-01 2024-01-04 Novartis Ag Binding molecules against BCMA and uses thereof
KR102923588B1 (ko) * 2019-04-10 2026-02-05 스프링웍스 테라퓨틱스, 인크. 항 bcma 항체 및 감마 세크레타제 억제제의 조합 요법
EP4010322B1 (en) * 2019-08-09 2025-11-05 Pfizer Inc. Solid state forms of (s)-2-(((s)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-n-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1h-imidazol-4-yl)pentanamide and uses thereof

Also Published As

Publication number Publication date
WO2021183934A1 (en) 2021-09-16
JP7781764B2 (ja) 2025-12-08
BR112022018251A2 (pt) 2022-11-08
US20230121547A1 (en) 2023-04-20
IL296075A (en) 2022-11-01
ZA202209989B (en) 2025-12-17
AU2021236340A1 (en) 2022-09-29
JP2023517243A (ja) 2023-04-24
EP4132515A1 (en) 2023-02-15
CO2022014388A2 (es) 2023-02-16
JP2025168430A (ja) 2025-11-07
TW202200132A (zh) 2022-01-01
CN115916188A (zh) 2023-04-04
AR121566A1 (es) 2022-06-15
CL2022002479A1 (es) 2023-08-18
MX2022011258A (es) 2023-01-11
KR20230009873A (ko) 2023-01-17
PE20230614A1 (es) 2023-04-14

Similar Documents

Publication Publication Date Title
US20230121547A1 (en) A combination therapy with nirogacestat and a bcma-directed therapy and uses thereof
CN109562106B (zh) Cxcr4抑制剂及其用途
AU2023274176A1 (en) Methods of treating and preventing graft versus host disease
WO2023049831A1 (en) Treatment of human papillomavirus-associated cancers by pd-l1 inhibitors
KR20240019391A (ko) 혈액 장애를 치료하기 위한 화합물 및 조성물
SG191744A1 (en) Imidazo [4, 5 -c] quinolin- 2 -one compound and its use as pi3 kinase / mtor dual inhibitor
MX2007001054A (es) Imidazo[4,5-d]pirimidinas, sus usos y metodos de preparacion.
CA3084905A1 (en) Composition and method for treating peripheral t-cell lymphoma and cutaneous t-cell lymphoma
US11872220B2 (en) Methods and compositions for treating B-cell malignancies
WO2019241644A1 (en) Novel small molecule anticancer agents, combinations and uses thereof
Coutelier et al. Effect of sulfur mustard on murine lymphocytes
WO2021143792A1 (zh) 哌啶类化合物及其制备方法和医药用途
IL324452A (en) Alternative phenyl oxazolone compounds
EA051675B1 (ru) Комбинированная терапия с нирогацестатом и bcma-направленной терапией и ее применение
EP4724149A1 (en) Spirocyclic substituted oxoisoindolinyl piperidine-2,6-dione compound
EP4731308A1 (en) Substituted oxoisoindolinyl piperidine-2,6-dione compound as anticancer agent
CN115317493A (zh) 一种硼酸类小分子化合物在制备增强免疫检查点抑制剂疗效及治疗白血病药物中的应用
WO2023005992A1 (zh) 药物组合及其应用
CN114206869A (zh) Cxcr4抑制剂和其用途
CN119074708A (zh) 氟他胺治疗头颈鳞癌的应用及其减毒增效组合物
WO2023091550A1 (en) Methods of treating estrogen receptor-associated diseases
Demidem et al. Sensitization of AIDS related non-Hodgkin's B lymphoma cell lines to cytotoxic drugs toxins by interferon-gamma
ZA200201649B (en) Fused pyrrolecarboxamides: GABA brain receptor ligands.
CA2941703A1 (en) Cancer stem cell targeting compounds

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250307

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250307

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250307

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20250311

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20250311

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250311

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250312

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250312

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250312

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250312

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20250430

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250512

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20260218